Glavine Paul purchased $1.0M of HELP

Glavine Paul (Chief Growth Officer) purchased 90,000 shares of CYBIN INC. (HELP) at $11.59 ($1.04M total) on 2026-08-31.

Original reporting
SEC EDGAR · Glavine Paul
Published Sep 9, 2026, 3:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 3:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HELP
Bullish
high confidence
Mentioned
$HELP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HELPBullishMed
01

Why it matters

The $1.04M purchase by the Chief Growth Officer adds to his existing large stake, indicating strong confidence in Cybin's prospects.

02

Market read

Insider buying of this magnitude can trigger short‑term buying interest and may influence analyst sentiment.

03

What to watch

Potential upcoming clinical trial results or regulatory filings not disclosed in the Form 4.

Relevance 7/10Novelty 7/10Timing: transaction dated 2026-08-31, filed 2026-09-09

Background

Form 4 filings disclose insider trades; C‑level purchases are closely watched by traders for sentiment cues.

Company-level read

Ticker impact

$HELPBullishHigh confidence
Context

Chief Growth Officer Glavine Paul bought 90,000 shares of Cybin Inc. for $1.04M, increasing his stake to over 4 million shares.

Expected impact

Potential modest upward pressure as market absorbs the insider buying signal.

Evidence & confidence

C‑level insider purchases are viewed as strong bullish cues, especially when the transaction size exceeds $1M.

Market effects

May boost sentiment for biotech and pharma sector peers as insider confidence spreads.

Limited to US biotech market; no broader regional effect.

Minimal global impact beyond sector perception.

Counterpoint

Insider buying could be a window dressing move ahead of upcoming dilution or negative news.

Key entities

  • Cybin Inc.

    Biopharma company developing psychedelic therapeutics.

  • Glavine Paul

    Chief Growth Officer of Cybin Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HELPMed

HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data

HELP stock declined despite positive late-stage trial data for its depression drug, HLP003. The drug showed significant improvements in patients, with 56% seeing at least a 50% improvement at six weeks. Analysts like Lucid Capital raised their price target to $79, citing strong results, while Jefferies and Barclays maintained 'Buy' and 'Overweight' ratings, respectively. Retail sentiment on Stocktwits turned 'extremely bullish'.

$HELPMedAI 8/10

Helus Pharma falls 10.5% despite positive HLP003 trial

Helus Pharma (HELP) reported positive results for its experimental drug HLP003, meeting the primary endpoint in a late-stage depression trial. Despite this, shares fell 10.5% to $7.94, with three serious adverse events disclosed. Analysts noted strong efficacy and no fundamental reason for the decline. The company is also developing HLP004 for anxiety and expects to identify an HLP005 candidate in late 2027.

MedAI 8/10

Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

HighAI 8/10

Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump

Helus Pharma reported that its psychedelic drug, HLP003, showed significant improvement in depression symptoms in a late-stage trial. The drug, a modified version of psilocin, is designed to be used with standard antidepressants. The company's shares rose over 20% in premarket trading. According to Helus, 56.3% of patients treated with HLP003 saw their symptoms cut by at least half, compared with 28.2% on placebo.